BHVN - Biohaven Pharmaceutical Holding Company Ltd.

NYSE - NYSE Delayed Price. Currency in USD
67.41
+1.13 (+1.70%)
At close: 4:00PM EDT

67.41 0.00 (0.00%)
After hours: 6:04PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close66.28
Open65.69
Bid56.00 x 1300
Ask68.00 x 800
Day's Range65.37 - 69.36
52 Week Range26.56 - 69.36
Volume897,861
Avg. Volume938,348
Market Cap3.946B
Beta (5Y Monthly)0.46
PE Ratio (TTM)N/A
EPS (TTM)-9.52
Earnings DateAug 10, 2020 - Aug 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est68.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Kleo Pharmaceuticals to Present Corporate Overview and Pipeline Update at Jefferies Virtual Healthcare Conference

    NEW HAVEN, Conn., June 01, 2020 -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to.

  • 3 Reasons Why Biohaven Pharmaceuticals' Stock Is Taking Off
    Motley Fool

    3 Reasons Why Biohaven Pharmaceuticals' Stock Is Taking Off

    A hot new migraine drug, positive financials, and several promising drug candidates in late-stage trials are luring investors to this stock.

  • GlobeNewswire

    Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma

    NEW HAVEN, Conn., May 21, 2020 -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to.

  • Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC™ ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
    PR Newswire

    Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC™ ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that it will present data from 25 accepted abstracts demonstrating the efficacy, safety, tolerability, and pharmacoeconomic value of NURTEC (rimegepant) on the 2020 American Academy of Neurology (AAN) Science Highlights virtual platform. NURTEC™ ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist in an orally disintegrating tablet (ODT) approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults.

  • GlobeNewswire

    Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting

    Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, today announced preclinical data for the company’s lead program, KP1237 in combination with autologous, cytokine-induced, memory-like (CIML) natural killer (NK) cells with low dose IL-2 in multiple myeloma (MM). This research, in collaboration with Dr. Rizwan Romee, Director of the Haploidentical Donor Transplantation Program at the Dana Farber Cancer Institute, will be presented as a poster and highlight the activity of the combination of KP1237 with CIML NK cells against CD38-expressing MM target cells.

  • Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments
    PR Newswire

    Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended March 31, 2020, and provided a review of recent accomplishments and anticipated upcoming milestones.

  • Why Biohaven (BHVN) Might Surprise This Earnings Season
    Zacks

    Why Biohaven (BHVN) Might Surprise This Earnings Season

    Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East
    PR Newswire

    Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Genpharm Services, a leading partner for innovative pharmaceuticals in Dubai, announced today an agreement to distribute NURTEC™ ODT (rimegepant) in the Middle East and Gulf countries. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.

  • Biohaven Changing 2020 Annual Meeting Of Shareholders To Virtual-Only Meeting Format Due To COVID-19
    PR Newswire

    Biohaven Changing 2020 Annual Meeting Of Shareholders To Virtual-Only Meeting Format Due To COVID-19

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that its Board of Directors has decided to hold the company's 2020 Annual Meeting of Shareholders on Thursday, April 30, 2020 at 10:00 a.m. Atlantic Time (9:00 a.m. Eastern Time) in a virtual-only meeting format due to the evolving nature of the COVID-19 pandemic and taking into account the guidance and protocols issued by public health and government authorities.

  • Biohaven Enters Into Partnership With Medison Pharma To Distribute NURTEC™ ODT In Israel
    PR Newswire

    Biohaven Enters Into Partnership With Medison Pharma To Distribute NURTEC™ ODT In Israel

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Medison Pharma, Israel's leading partner for innovative pharmaceuticals, announced today an agreement to distribute NURTEC™ ODT (rimegepant) in Israel. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.

  • Biohaven Pharmaceutical Needs More Bottom Development Before Becoming a Buy
    TheStreet.com

    Biohaven Pharmaceutical Needs More Bottom Development Before Becoming a Buy

    In another of his "Executive Decision" segments on Mad Money Wednesday night, Jim Cramer checked in with Dr. Vlad Coric, CEO of Biohaven Pharmaceutical Holding Co. , which recently received approval for Nurtec, its oral treatment for migraines. Coric said that not only has Nurtec received approval for the treatment of migraines, they are also getting positive results from their prevention studies as well. Cramer noted that Nurtec is proving to be a much-needed supplement for monthly injections for migraines, which often see patients suffer breakthrough headaches during the week before their next shot.

  • Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection
    PR Newswire

    Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it submitted Pre-IND/IND material to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of vazegepant, an intranasal, high-affinity calcitonin gene-related peptide (CGRP) receptor antagonist, for the treatment of COVID-19 infection associated pulmonary complications. The IND was approved by the Division of Pulmonary, Allergy, and Critical Care at FDA on April 8th and Biohaven was informed that the study may proceed immediately. Vazegepant is currently advancing to Phase 3 development for the acute treatment of migraine in adults under the Division of Neurology, having recently reported a successful end of Phase 2 clinical and nonclinical interaction with FDA.

  • Does Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Have A High Beta?
    Simply Wall St.

    Does Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Have A High Beta?

    Anyone researching Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) might want to consider the historical...

  • Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT
    PR Newswire

    Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced a collaboration with Cove, a company providing specialized care and access to innovative treatments for migraine sufferers via telemedicine services in the United States. The collaboration seeks to facilitate telemedicine evaluation for migraine sufferers while patients are increasingly looking to remote evaluations during this time of unprecedented decreased access to routine office visits.

  • Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy
    PR Newswire

    Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy

    Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that it has entered into a research collaboration with South Korea -based Green Cross LabCell (GCLC), a pioneer in the next generation of allogeneic, or "off-the-shelf" natural killer (NK) cell therapies, to rapidly advance testing of both advanced technology platforms in combination as a potential therapy for COVID-19 patients.

  • Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine
    PR Newswire

    Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results in its randomized, placebo-controlled pivotal clinical trial (NCT03732638) evaluating the efficacy and safety of oral rimegepant 75 mg for the preventive treatment of migraine in both episodic and chronic migraine patients. The study met the primary endpoint, demonstrating a statistically significant reduction from baseline in monthly migraine days in patients treated with rimegepant compared with placebo. Those receiving rimegepant 75 mg every other day (n=348) experienced a statistically significant 4.5 day reduction from baseline in monthly migraine days, compared to a 3.7 day reduction in the placebo group (n=347; p=0.0176). Among study participants not taking concomitant preventive treatment, there was a 4.9 day reduction in monthly migraine days in the rimegepant group (n=273) compared with a 3.7 day reduction in the placebo group (n=269; nominal p=0.0020). A total of 22% of the study participants were taking a concurrent preventive treatment, including topiramate and amitriptyline. Importantly, 48% of the rimegepant group had at least a 50% reduction from baseline in the mean number of moderate to severe migraine days per month compared to 41% in the placebo group.

  • Hedge Funds Are Souring On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
    Insider Monkey

    Hedge Funds Are Souring On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
    PR Newswire

    Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or, the "Company") today announced a successful end of Phase 2 clinical and nonclinical interaction with the U.S. Food and Drug Administration (FDA) for intranasal vazegepant for the acute treatment of migraine. The Company addressed all issues raised by the FDA and will advance the 10 mg dose of intranasal vazegepant into a double-blind, placebo-controlled Phase 3 clinical trial. Biohaven previously reported that intranasal vazegepant 10 and 20 mg achieved statistical superiority to placebo on the co-primary regulatory endpoints of pain freedom and freedom from most bothersome symptom at 2 hours in a Phase 2/3 dose finding trial.

  • Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
    PR Newswire

    Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a biopharmaceutical company focused on the development and commercialization of innovative best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, announced today that the Company's myeloperoxidase (MPO) inhibitor, verdiperstat, received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of multiple system atrophy (MSA).

  • Biohaven Announces Patient Savings Program Where Patients Can Pay as Little as $0 for NURTEC™ ODT (rimegepant 75 mg) for the Acute Treatment of Migraine in Adults
    PR Newswire

    Biohaven Announces Patient Savings Program Where Patients Can Pay as Little as $0 for NURTEC™ ODT (rimegepant 75 mg) for the Acute Treatment of Migraine in Adults

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced a Patient Savings Program for NURTEC™ ODT (rimegepant) that is now available for eligible commercially insured patients. The co-pay savings card can be obtained at the www.nurtec.com website after 12pm today. The U.S. Food and Drug Administration (FDA) approved NURTEC ODT for the acute treatment of migraine in adults on February 27, 2020. NURTEC ODT, which disperses almost instantly in a person's mouth without the need for water, works by blocking the CGRP receptor, treating a root cause of migraine. NURTEC ODT is not indicated for the preventive treatment of migraine.

  • Biohaven's NURTEC™ ODT (rimegepant 75mg) is Now Available in U.S. Pharmacies for the Acute Treatment of Migraine in Adults
    PR Newswire

    Biohaven's NURTEC™ ODT (rimegepant 75mg) is Now Available in U.S. Pharmacies for the Acute Treatment of Migraine in Adults

    Biohaven Pharmaceutical Holding Company (NYSE: BHVN) today announced that NURTEC™ ODT (rimegepant) is now available by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved NURTEC ODT for the acute treatment of migraine in adults on February 27, 2020. NURTEC ODT, which disperses almost instantly in a person's mouth without the need for water, works by blocking the CGRP receptor, treating a root cause of migraine. NURTEC ODT is not indicated for the preventive treatment of migraine.

  • Benzinga

    The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...

  • Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults
    PR Newswire

    Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults. NURTEC ODT is the first FDA-approved product for Biohaven, a company dedicated to advancing innovative therapies for neurological diseases.

  • Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Recent Business Developments
    PR Newswire

    Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Recent Business Developments

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the fourth quarter and year ended December 31, 2019, and provided a review of recent accomplishments and anticipated upcoming milestones.

  • Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
    PR Newswire

    Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board

    Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today the appointment of CEO Doug Manion, MD, FCRP (C), to Chairman of the Board. He will replace Thomas J. Lynch, Jr., MD, the former Chief Scientific Officer of Bristol-Myers Squibb Company (BMS), who was recently appointed president and director of the Fred Hutchinson Cancer Research Center. Tom will vacate his directorship with Kleo, but will remain a consultant to the company.